Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 9/20 | 0.67 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29550978 | 0.96 | GHSR (0.63) | GHSRKISS1R | |
| SCHEMBL29551214 | 0.95 | GHSR (0.63) | GHSR | |
| SCHEMBL29551293 | 0.95 | GHSR (0.64) | GHSRKISS1R | |
| SCHEMBL30276253 | 0.95 | GHSR (0.64) | GHSRKISS1R | |
| SCHEMBL30276276 | 0.94 | GHSR (0.63) | GHSRKISS1R | |
| SCHEMBL29550650 | 0.94 | GHSR (0.63) | GHSRKISS1R | |
| SCHEMBL31171030 | 0.93 | GHSR (0.70) | GHSR | |
| SCHEMBL29551222 | 0.93 | GHSR (0.60) | GHSR | |
| SCHEMBL29565376 | 0.92 | GHSR (0.61) | GHSRKISS1R | |
| SCHEMBL29365946 | 0.92 | GHSR (0.64) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220047679-A1 | COMBINATION THERAPY | ANTISENSE THERAPEUTICS LTD (AU) | 2022-02-17 | — | — | US | claimed |
| US-20250154219-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2025-05-15 | — | — | US | disclosed |
| US-12110318-B2 | Peptide analogs | ADEPTHERA LLC (US) | 2024-10-08 | — | — | US | disclosed |
| US-20220324935-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2022-10-13 | — | — | US | disclosed |
| US-11390657-B2 | Peptide analogs | ADEPTHERA LLC (US) | 2022-07-19 | — | — | US | disclosed |
| US-20220047679-A1 | COMBINATION THERAPY | ANTISENSE THERAPEUTICS LTD (AU) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047679-A1 | COMBINATION THERAPY | GHSR, GHRHR, IGF1R | GHSR 1/4885KISS1R 390/4885 |
| US-12110318-B2 | Peptide analogs | RAMP1, RAMP3, RAMP2 | GHSR 63/4885KISS1R 327/4885 |
| US-20220324935-A1 | PEPTIDE ANALOGS | RAMP1, RAMP2, RAMP3 | GHSR 68/4885KISS1R 503/4885 |
| US-20250154219-A1 | PEPTIDE ANALOGS | RAMP1, RAMP2, RAMP3 | GHSR 68/4885KISS1R 503/4885 |
| US-11390657-B2 | Peptide analogs | RAMP1, RAMP3, RAMP2 | GHSR 63/4885KISS1R 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.